The Clinical Follow-up Core provides patients to support the translational and clinical portions of Projects 2, 3, 4, 5, and 6 of the SPORE. This patient follow-up data will be gathered prospectively on patients who undergo prostate biopsy, primary therapy for early stage prostate cancer or therapy for hormone refractory prostate cancer. These therapies consist of radical retropubic prostatectomy, external beam radiotherapy, prostate brachytherapy by permanent interstitial implantation or hormonal therapy. Patients who have failed primary external beam radiotherapy will be identified and recruited for Projects 5 and 6 of the SPORE. Patients will be recruited for participation in the SPORE translational research and clinical trials in this core which will operate jointly in the Departments of Urology, Radiation Oncology, and Medical Oncology. The follow-up test schedule for primary patients is specified from treatment initiation. Database managers in each department will assist in recruiting patients for these studies, schedule tests and follow-up appointments, and gather data. Prospective follow-up data collection in support of the biomarker Projects 2 and 3 and will include serum prostate specific antigen (PSA), physical examination, and disease status. Data storage and analysis will be conducted by the Biostatistics Core.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center (P50)
Project #
5P50CA091956-02
Application #
6641465
Study Section
Special Emphasis Panel (ZCA1)
Project Start
2002-08-01
Project End
2003-07-31
Budget Start
Budget End
Support Year
2
Fiscal Year
2002
Total Cost
Indirect Cost
Name
Mayo Clinic, Rochester
Department
Type
DUNS #
City
Rochester
State
MN
Country
United States
Zip Code
55905
Guerrico, Anatilde Gonzalez; Hillman, David; Karnes, Jeffery et al. (2017) Roles of kallikrein-2 biomarkers (free-hK2 and pro-hK2) for predicting prostate cancer progression-free survival. J Circ Biomark 6:1849454417720151
Hearn, Jason W D; AbuAli, Ghada; Reichard, Chad A et al. (2016) HSD3B1 and resistance to androgen-deprivation therapy in prostate cancer: a retrospective, multicohort study. Lancet Oncol 17:1435-1444
Spratt, Daniel E; Evans, Michael J; Davis, Brian J et al. (2015) Androgen Receptor Upregulation Mediates Radioresistance after Ionizing Radiation. Cancer Res 75:4688-96
Lu, Ji; Lonergan, Peter E; Nacusi, Lucas P et al. (2015) The cistrome and gene signature of androgen receptor splice variants in castration resistant prostate cancer cells. J Urol 193:690-8
Urban, Matthew W; Wang, Chenyi; Alizad, Azra et al. (2015) Complex background suppression for vibro-acoustography images. Ultrasonics 56:456-72
Cooperberg, Matthew R; Davicioni, Elai; Crisan, Anamaria et al. (2015) Combined value of validated clinical and genomic risk stratification tools for predicting prostate cancer mortality in a high-risk prostatectomy cohort. Eur Urol 67:326-33
Alshalalfa, Mohammed; Crisan, Anamaria; Vergara, Ismael A et al. (2015) Clinical and genomic analysis of metastatic prostate cancer progression with a background of postoperative biochemical recurrence. BJU Int 116:556-67
Loeb, Stacy; Sanda, Martin G; Broyles, Dennis L et al. (2015) The prostate health index selectively identifies clinically significant prostate cancer. J Urol 193:1163-9
Ahmed, Kamran A; Davis, Brian J; Mynderse, Lance A et al. (2014) Comparison of biochemical failure rates between permanent prostate brachytherapy and radical retropubic prostatectomy as a function of posttherapy PSA nadir plus 'X'. Radiat Oncol 9:171
Wu, Qiang; Kohli, Manish; Bergen 3rd, H Robert et al. (2014) Preclinical evaluation of the supercritical extract of azadirachta indica (neem) leaves in vitro and in vivo on inhibition of prostate cancer tumor growth. Mol Cancer Ther 13:1067-77

Showing the most recent 10 out of 206 publications